NSPR logo

INSPIREMD INC

NSPRNASDAQ
🏆 #4633 by market capEarnings Nov 2US Equity
$887.22▲ $68.85 (+7.76%)
Simulated price
🔔
Track NSPR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$33M
Small Cap
📈Revenue Growth (YoY)
+28.1%
High Growth
📊Gross Margin
18.1%
Thin
💵FCF Margin
-391.7%
Thin
⚖️P/S Ratio
3.0x
Fair
Otter Score
56
Weak
No chart data available for NSPR.

Trading Snapshot

Day Range
$883.99 – $892.34
52-Week Range
$0.63 – $2.57
Volume
$2.75B
Avg Volume
$3.28B
Shares Outstanding
46.8M
Next Earnings
Dec 9, 2026

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$2M
P/E Ratio
-1.4
P/S Ratio
3.0x
EPS (TTM)
$-0.52
Dividend Yield
0.00%
Dilution (1yr)
+50.3%

Why Investors Own NSPR

  • ✓High-growth profile — revenue up +50.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 70% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NSPR logo

INSPIREMD INC

NSPR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9M▲ +28.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.5%▲ +37.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$49M▲ +46.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$37M▲ +58.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
73.5M▲ +50.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▼ −$11M YoY
StockOtter · stockotter.space

About INSPIREMD INC

InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$994.71
▲ +12.1% Upside
High Target$1,224.04
Low Target$930.53
Based on 40 analysts

Latest News & Updates

🚀
Barron’s·2h ago

INSPIREMD INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift NSPR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

INSPIREMD INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.